Navigation Links
DecisionView Launches StudyOptimizer(TM) 4
Date:12/10/2009

SAN FRANCISCO, Dec. 10 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer 4, the latest iteration of its Web-based solution. Currently in use by several major global pharmaceutical companies, DecisionView's flagship product now includes advanced historical analysis and templates capabilities, as well as enhancements to its predictive analytics technology. For the first time, clinical trial managers have a comprehensive 360 degree view of their organization's clinical trial patient recruitment performance at their fingertips with:

  • Past enrollment patterns and metrics
  • Present enrollment actual performance compared to plans
  • Future forecasted end dates of trials based on performance to date

"StudyOptimizer's advanced predictive analytics and visualizations, automated in a consistent, standardized approach to clinical trial planning, has enabled GSK to double the frequency with which trials are completed on-time," said Alex Lancksweert, Director of Business Performance Analytics at GlaxoSmithKline. "StudyOptimizer has enabled our teams to work in a more collaborative style to create robust plans grounded on empirically justified assumptions, and to streamline decision making by more effectively communicating trial progress to a dispersed study team and participating research sites. StudyOptimizer 4 brings historical analysis into that equation, empowering those teams to make decisions informed by hindsight as well as foresight."

"Clinical trial patient enrollment is one of the most promising areas for pharmaceutical companies to look at for operational performance improvements," said Alan Louie, Ph.D., Research Director, IDC. "The ability to capture, analyze and leverage historical clinical trial enrollment data in planning future patient recruitment efforts provides a critical baseline that life sciences organizations need in order to benchmark and improve these processes."

StudyOptimizer allows clinical trial managers to plan, track, diagnose and correct enrollment plans via a single centralized Web-based application that captures and aggregates clinical trial patient enrollment data from across the organization. The application uses predictive analytics to forecast enrollment trends and estimate completion dates, which are dynamically updated based on actual enrollment patterns and give clinical trial managers the necessary information to measure actual and projected performance against plan. Because StudyOptimizer's clinical trial software enables faster, more predictable clinical enrollment, trials can finish on budget and on schedule.

StudyOptimizer 4 allows for improved hindsight and foresight as well as productivity and uptime. New features include:

  • Historical analysis to benchmark and compare the enrollment performance of past clinical trials
  • Plan templates with pre-defined enrollment plans based on past studies or historical averages
  • Enhanced predictive analytics technology with improved forecasting parameters and thresholds
  • Confidence intervals that provide prediction ranges around projection curves
  • Enhanced data integration technology that increase the availability of current data
  • Enhanced data analysis with advanced OLAP (Online Analytical Processing) cube technology
  • Improved user interface designed to streamline navigation and enhance user experience

"With StudyOptimizer 4, clinical trial managers will now have a comprehensive view of patient enrollment enabling them to easily create and modify patient recruitment plans to optimize the delivery timeframe and related costs of clinical trials," said Gonzalo Castro, Vice President of Products at DecisionView. "This advanced functionality demonstrates our continued commitment to provide the industry with 'best-in-class' clinical trial enrollment optimization solutions."

Recently, DecisionView announced the availability of the Software-as-a-Service (SaaS) version of StudyOptimizer. Through the company's SaaS offering, StudyOptimizer is available on a single or multiple trial basis and includes hosting, implementation and support services from the company.

For more information on StudyOptimizer 4 visit: http://decisionview.com/news/studyoptimizer-release-4.html

About DecisionView

DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by four of the top ten global pharmaceutical companies, and has been used on over 750 clinical studies with over 120,000 subjects enrolled in over ten different therapeutic areas. Primary investors in the company include Granite Ventures, Adobe Ventures, and Aeris Capital.

SOURCE DecisionView Inc.


'/>"/>
SOURCE DecisionView Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicares Power Mobility Benefit
2. FDA Launches Orphan Drug Workshop at KGI
3. Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture
4. New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
5. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology
8. NightHawk Radiology Launches Redesigned Quality Assurance Program
9. eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims
10. Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace
11. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... FRANCISCO , January 24, 2017 ... a value of USD 3.8 billion by 2025, according ... The market growth can be attributed to the rising ... about early diagnosis of micro calcifications in breast tissue. ... Foundation, CDC, and Breast Cancer Organization are promoting the ...
(Date:1/24/2017)... Stock-Callers.com today has issued research reports on four ... Mallinckrodt PLC (NYSE: MNK ), Akorn Inc. (NASDAQ: ... DPLO ). According to pharmaceutical manufacturer PCI Synthesis, there ... Generic Drugs industry, including a possible reduction in FDA red ... a speedier FDA approval process that could reduce its backlog ...
(Date:1/24/2017)... 2017 Optoelectronic components have the capability ... interaction of these components with light makes them ... of applications. These components are primarily used in ... healthcare among others. Growing application across ... power consumption, reliability, scalability, and performance is fueling ...
Breaking Medicine Technology:
(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... ... Novel of Miracles”: a beautiful and poignant glimpse into the unexpected consequences of a ... Would Have Dreamed: A Novel of Miracles” is the creation of published author, Sharon Lee ... shares that she started her spiritual journey later in life, but mentions, “I have had ...
(Date:1/24/2017)... ... 2017 , ... “The Octagon of Spiritual Balances”: a guide for the ... creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, ... religious education and a master degree in theology. , ““The Octagon of Spiritual Balances” ...
(Date:1/24/2017)... Raton, FL (PRWEB) , ... January 23, 2017 ... ... unique, highly refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee ... nutritional products. , CLICK® Coffee Protein Drink Mix has become popular among health-conscious ...
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation ... of the Mexico City Policy, also known as the Global Gag Rule, last ... action, prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family ...
Breaking Medicine News(10 mins):